Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Pezzetta

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecular Pharmaceutics|May 12, 2006
Computational models for identifying potential P-glycoprotein substrates and inhibitorsPatrizia Crivori, Benedetta Reinach, Daniele Pezzetta, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 24, 2007
Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systemsPatrizia Crivori, Amedea Morelli, Daniele Pezzetta, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|November 25, 2003
Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservationMarcella Martignoni, Mario Monshouwer, Ruben de Kanter, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 4, 2015
In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitorValentina Cenacchi, Rosangela Battaglia, Flavio Cinato, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2011
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitorItalo Beria, Roberto T Bossi, Maria Gabriella Brasca, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitorsItalo Beria, Barbara Valsasina, Maria Gabriella Brasca, et al.
Journal of Medicinal Chemistry|July 30, 2015
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer TherapyGianluca Papeo, Helena Posteri, Daniela Borghi, et al.
Journal of Medicinal Chemistry|January 1, 2009
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discoveryMaria Menichincheri, Alberto Bargiotti, Jens Berthelsen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecular Pharmaceutics|May 12, 2006
Computational models for identifying potential P-glycoprotein substrates and inhibitorsPatrizia Crivori, Benedetta Reinach, Daniele Pezzetta, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 24, 2007
Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systemsPatrizia Crivori, Amedea Morelli, Daniele Pezzetta, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|November 25, 2003
Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservationMarcella Martignoni, Mario Monshouwer, Ruben de Kanter, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 4, 2015
In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitorValentina Cenacchi, Rosangela Battaglia, Flavio Cinato, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2011
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitorItalo Beria, Roberto T Bossi, Maria Gabriella Brasca, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitorsItalo Beria, Barbara Valsasina, Maria Gabriella Brasca, et al.
Journal of Medicinal Chemistry|July 30, 2015
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer TherapyGianluca Papeo, Helena Posteri, Daniela Borghi, et al.
Journal of Medicinal Chemistry|January 1, 2009
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discoveryMaria Menichincheri, Alberto Bargiotti, Jens Berthelsen, et al.
Pageof 1